Single anti-PD-1 monoclonal antibody infusions show only modest clinical efficacy [8]; however, in combination with hypomethylating agents, they represent promising treatments for relapsed/refractory AML patients as well as elderly patients as a first-line therapy option (recently reviewed in [9]). The gene discussed is PDCD1; the disease is acute myeloid leukemia.